A first-in-class stapled peptide to target type 2 diabetes at its root

At AdipoPharma, we are focused on the adipose tissue as our therapeutic target for type 2 diabetes. Utilizing our strong expertise and knowledge of the adipocyte biology and its critical metabolic role as our focus, AdipoPharma has developed a first-in-class of Adipeutic drug that targets the adipose tissue.

PATAS, the lead therapeutic compound

PATAS is an innovative peptide which targets a specific protein-protein interaction of ALMS1 in the adipocyte. PATAS has been successfully shown in pre-clinical studies to trigger insulin-independent glucose absorption in the adipocyte resulting in long-term beneficial impact through modifications in lipid signalling.

Significant beneficial systemic effects have been established in pre-clinical studies both in vitro and in vivo. PATAS has demonstrated remarkable anti-diabetic effects, an improvement of pancreatic functions associated with increased insulin secretion, while reducing comorbidities like liver steatosis, fibrosis, cardiovascular complications and most notably has a positive impact on ceramides.